Literature DB >> 17018691

A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor.

Jillian G Baker1, Stephen J Hill.   

Abstract

The antagonist affinity for a given receptor is traditionally considered to be constant, reflecting the chemical nature of the specific ligand-receptor interaction. However, recent observations with all three beta-adrenoceptors have cast doubt on this basic pharmacological principle. The extent to which this finding applies to other G protein-coupled receptors and their interaction with different G proteins is unknown. Therefore, we studied the influence of different agonists on antagonist affinity measurements for Gi- and Gs-coupled conformations of the adenosine A1-receptor in Chinese hamster ovary cells stably expressing the human adenosine A1-receptor and a cAMP-response element (CRE)-secreted placental alkaline phosphatase reporter gene. Gi-coupled inhibition of [3H]cAMP accumulation via the A1-receptor was observed at low concentrations of agonist; however, a small increase in [3H]cAMP accumulation was also seen at higher agonist concentrations. This biphasic response was more evident for A1-stimulated CRE-gene transcription. The inhibitory component was abolished by pretreatment with pertussis toxin, whereas the stimulatory component was augmented, suggesting that the responses were due to an A1-Gi-coupled inhibition followed by an A1-Gs-coupled stimulation. However, the antagonist affinity values measured at the Gi-coupled and Gs-coupled conformations of the receptor were the same in both functional responses and whole-cell binding. Thus, in marked contrast to the beta-adrenoceptors, the A1-receptor conforms to the long-held principle of pharmacology that antagonist affinity measurements are constant regardless of the response being measured and the competing agonist used to stimulate that response. This was true even when the receptor was shown, in the same assay, to exist in two different conformational states coupled to two different G proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018691     DOI: 10.1124/jpet.106.113589

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.

Authors:  Stephen J Hill; Christine Williams; Lauren T May
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 3.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

4.  Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression.

Authors:  Mark J Wall; Emily Hill; Robert Huckstepp; Kerry Barkan; Giuseppe Deganutti; Michele Leuenberger; Barbara Preti; Ian Winfield; Sabrina Carvalho; Anna Suchankova; Haifeng Wei; Dewi Safitri; Xianglin Huang; Wendy Imlach; Circe La Mache; Eve Dean; Cherise Hume; Stephanie Hayward; Jess Oliver; Fei-Yue Zhao; David Spanswick; Christopher A Reynolds; Martin Lochner; Graham Ladds; Bruno G Frenguelli
Journal:  Nat Commun       Date:  2022-07-18       Impact factor: 17.694

5.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

6.  A study of antagonist affinities for the human histamine H2 receptor.

Authors:  J G Baker
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

7.  Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells.

Authors:  Jillian G Baker
Journal:  BMC Pharmacol       Date:  2008-06-06

8.  Application of BRET to monitor ligand binding to GPCRs.

Authors:  Stephen J Hill; Kevin D G Pfleger; Leigh A Stoddart; Elizabeth K M Johnstone; Amanda J Wheal; Joëlle Goulding; Matthew B Robers; Thomas Machleidt; Keith V Wood
Journal:  Nat Methods       Date:  2015-06-01       Impact factor: 28.547

9.  Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.

Authors:  Jillian G Baker; Richard Middleton; Luke Adams; Lauren T May; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2010-01-26       Impact factor: 8.739

Review 10.  Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.

Authors:  Jillian G Baker; Stephen J Hill
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.